Current Medical Research and Opinion最新文献

{"title":"Effectiveness of molnupiravir for the treatment of COVID-19: a systematic literature review of real-world observational studies.","authors":"Samantha G Bromfield, Ramu Periyasamy, Veeri Rajendra Babu, Amy Puenpatom, Deanna D Hill","doi":"10.1080/03007995.2025.2551227","DOIUrl":"10.1080/03007995.2025.2551227","url":null,"abstract":"<p><strong>Objective: </strong>Molnupiravir (MOV), an oral antiviral, is prescribed to treat adult patients with mild-to-moderate COVID-19 at risk of progressing to severe disease. Previous systematic literature reviews (SLRs) have evaluated the effectiveness of MOV in the general population; however, evidence on high-risk population is lacking. This SLR assessed the real-world effectiveness of MOV for reducing the progression to severe COVID-19 outcomes in clinical settings, including high-risk or special populations (such as patients with type 2 diabetes, chronic respiratory diseases, immunocompromised conditions, older adults, and nursing home residents) who have limited alternative COVID-19 treatment options.</p><p><strong>Methods: </strong>We searched EMBASE and PubMed databases for studies published between 1 January 2021 and 24 May 2024, using predefined search terms related to MOV. Studies comparing MOV-treated with untreated groups of non-hospitalized adults at risk of progression to severe COVID-19 outcomes (hospitalization, death, and the composite of hospitalization/death) were included. Risk of bias of the included studies was assessed using the ROBINS-I tool.</p><p><strong>Results: </strong>Twenty-one general and special population studies were included. General population studies (<i>n</i> = 16) showed that MOV reduced the risk of death, hospitalization, and hospitalization/death. Special population studies (<i>n</i> = 10; five additional and five general population articles with subgroups of interest) also showed that MOV reduced the risk of the same outcomes, with a more pronounced effect in older adults (≥60 years). The wide range of risk reduction observed might be attributed to variability in COVID-19 hospitalization guidelines and vaccination status.</p><p><strong>Conclusions: </strong>Findings from this SLR suggest that MOV may reduce the risk of hospitalization, death, and hospitalization/death compared with untreated groups, including high-risk adults with underlying comorbidities. Further studies are needed to confirm the effectiveness of MOV in high-risk or special populations.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-22"},"PeriodicalIF":2.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Caregiver risk preferences for delaying loss of ambulation in Duchenne muscular dystrophy in the United States.","authors":"Jason Shafrin, Nadine Zawadzki, Moises Marin, Ivana Audhya, Lauren E Sedita, Natasha Kulkarni, Alexa C Klimchak","doi":"10.1080/03007995.2025.2550347","DOIUrl":"10.1080/03007995.2025.2550347","url":null,"abstract":"<p><strong>Objectives: </strong>Quantify caregiver risk preferences to inform the \"value of hope\" for Duchenne muscular dystrophy (DMD) therapies affecting time to loss of ambulation (LoA).</p><p><strong>Methods: </strong>Caregivers (medical decision-makers) of patients with DMD were surveyed to evaluate their preferences across 2 therapies with identical expected (average) time to LoA: 1 with variable (i.e. possibly longer or shorter than average) time to LoA and 1 with fixed (i.e. certain) time to LoA. Time to LoA with the fixed therapy was altered to determine the caregiver's indifference point. Study endpoints were (i) the share of caregivers who preferred the variable (vs fixed) time to LoA therapy; and (ii) the length of fixed time to LoA that would result in caregiver indifference between the variable and fixed therapies, calculated using parameter estimation by sequential testing. The base case examined therapy choice for a hypothetical ambulatory DMD patient aged 9 years; sensitivity analyses explored preferences for younger (aged 5) and older (aged 13) patients.</p><p><strong>Results: </strong>Among 103 caregivers surveyed, 72 (69.9%) preferred the variable time to LoA therapy for a hypothetical 9-year-old patient with DMD (<i>p</i> < 0.001). Caregivers were willing to give up 11.5 months (<i>p</i> < 0.001) of certain time to LoA for a chance of longer time to LoA. Caregivers' preference for the variable therapy decreased with hypothetical patient age at treatment initiation, from 72.8% (75/103) for age 5 (<i>p</i> < 0.001) to 60.2% (62/103) for age 13 (<i>p</i> = 0.048).</p><p><strong>Conclusions: </strong>Caregivers of patients with DMD demonstrated risk tolerance (positive value of hope) for therapies that could delay LoA.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive management of chronic kidney disease in the old population.","authors":"Ma Eugenia Portilla Franco, Adriana Puente-García, Luis M Pérez-Belmonte, Noemí Pérez, Sandra Ellingson, Fernando Tornero","doi":"10.1080/03007995.2025.2551217","DOIUrl":"10.1080/03007995.2025.2551217","url":null,"abstract":"<p><p>Chronic kidney disease (CKD) is a global issue that raises inflammation and heightens the risk of progressing to advanced CKD, requiring renal replacement therapy. It also significantly increases the likelihood of cardiovascular and vascular diseases, hospitalizations, functional decline, and reduced quality of life, particularly in older adults. CKD prevalence rises with age, affecting 25-30% of older adults. Despite that, the fact is that CKD is underdiagnosed in this population. Diagnosing CKD in older patients is difficult because accurate tests are limited, common serum creatinine-based formulas depend on muscle mass (often low in this group), and age-related renal function decline further complicates assessment. Comprehensive management can help achieve therapeutic goals in the old population with CKD through assessments and care plans. This care includes a combination of lifestyle changes, cardiovascular risk factors control, the use of drugs with proven renal and cardiovascular benefits, as well as the adequate management of specific clinical conditions, including the general clinical comorbidities, renal-related conditions and recognition of geriatric syndromes, helping patients manage their condition and involving them in decisions about their care. In this narrative review, the epidemiology, clinical profile and management of CKD in the old population are updated.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-14"},"PeriodicalIF":2.2,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2025 National Association of Specialty Pharmacy Annual Meeting & Expo: research presentation abstracts.","authors":"Sheila Arquette, Rebekah H Anguiano","doi":"10.1080/03007995.2025.2529096","DOIUrl":"https://doi.org/10.1080/03007995.2025.2529096","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":"41 sup2","pages":"1"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient involvement in publications: qualitative mapping of the current landscape within the pharmaceutical industry.","authors":"Adeline Rosenberg, Liz Clark, Graham R McClelland","doi":"10.1080/03007995.2025.2545496","DOIUrl":"https://doi.org/10.1080/03007995.2025.2545496","url":null,"abstract":"<p><strong>Objective: </strong>Patient involvement in pharmaceutical industry-sponsored publications is a rapidly evolving practice. It is supported by industry guidelines, but currently inconsistent across organizations. This study aimed to qualitatively map the landscape of current practices and gaps in patient involvement in peer-reviewed journal publications of pharmaceutical industry-sponsored research, and to define the specific roles and activities in which patients are involved.</p><p><strong>Methods: </strong>This qualitative, patient-led study was conducted using semi-structured interviews with purposively sampled experts in patient engagement and publications, including patients. Interviews were conducted online, transcribed, and thematically analysed. Landscape elements were visually mapped, and themes were generated through an inductive and experientially situated thematic analysis.</p><p><strong>Results: </strong>Interviews were conducted with 20 participants recruited globally, with a majority from the United Kingdom. Participants represented diverse stakeholder categories and reported patient involvement across all stages and aspects of the publication lifecycle, with patients both as external consultants and as professionals working within the system. Five overarching themes and 20 sub-themes were identified, including: patient identities and roles; principles and values; processes and practices; variations over time and across organizations; and impact. Significant gaps were identified in consistency, quality, and scale, for example including gaps in infrastructure barriers and diversity.</p><p><strong>Conclusions: </strong>Patient involvement in pharmaceutical publications is actively happening across the publication lifecycle and is rapidly growing and evolving. This study provides an evidence base <i>via</i> a qualitative mapping of the experiential landscape and highlights the need for established best practices to support consistency and quality in meaningful patient involvement in publications.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-15"},"PeriodicalIF":2.2,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Empowering patients through pharmacovigilance, transparency, and health literacy: a narrative review.","authors":"Magdia De Jesus, Golam Rabbani, Bertha Ferrer, Annlouise R Assaf, Mehnaz Bader, Brett R South, David P Leventhal, Paula Boyles, Stephen J Watt, Aida Habtezion","doi":"10.1080/03007995.2025.2534468","DOIUrl":"10.1080/03007995.2025.2534468","url":null,"abstract":"<p><p>At the intersection of pharmacovigilance (PV), Participant Data Return (PDR), and health literacy lies a social contract in healthcare. This implicit agreement reflects the shared responsibilities of pharmaceutical companies, healthcare providers, and patients to protect individual rights while promoting collective well-being. PV, PDR, and health literacy form a triad that ensures patients are not only protected but actively informed and engaged in their healthcare journey, fostering transparency, trust, and empowerment. PV, as a cornerstone of drug safety, upholds this social contract by continuously monitoring, identifying, and mitigating adverse reactions through collaboration with patients and healthcare providers. By encouraging patient participation in adverse event reporting, PV systems strengthen safety surveillance and reinforce the reciprocal nature of trust and accountability in healthcare. PDR strengthens this relationship by promoting ethical transparency in clinical trials. It gives participants access to their own data, supporting informed decisions and increasing public confidence in research. Health literacy empowers individuals by helping them understand and act upon health information. By leveraging tools and strategies that simplify complex medical data, pharmaceutical companies fulfill their responsibility to equip patients with the knowledge to make informed healthcare decisions. In doing so, all three honor the social contract by fostering equitable access to information and promoting patient-centered care. This manuscript highlights how PV, PDR, and health literacy work together to uphold ethical healthcare practices. Each contributes to a system built on trust, transparency, and shared responsibility; core values that reinforce positive patient outcomes and the foundation of a fair, effective healthcare ecosystem.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1249-1259"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effectiveness of single-inhaler fluticasone furoate/umeclidinium bromide/vilanterol in Chinese patients with symptomatic chronic obstructive pulmonary disease (COPD): a post-marketing, prospective, multicenter, observational study.","authors":"Jinfang Ma, Fangfang Dou, Wutie Zhou, Liyu Li, Junfei Zhu, Yupeng Zhang, Luqian Zhou, Lin Su, Lu Dong, Yifan He, Ark Ye, David Slade, Jinping Zheng","doi":"10.1080/03007995.2025.2536600","DOIUrl":"10.1080/03007995.2025.2536600","url":null,"abstract":"<p><strong>Objective: </strong>To assess the effectiveness of single-inhaler fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) in symptomatic chronic obstructive pulmonary disease (COPD) under real-world settings in China.</p><p><strong>Methods: </strong>In this single-arm, prospective, observational study, participants received 12 weeks of FF/UMEC/VI treatment. The primary outcome was change from baseline (CFB) in COPD Assessment Test (CAT) score at Week 12. Secondary outcomes included CFB in modified Medical Research Council (mMRC) dyspnea scale score and pre-dose forced expiratory volume in one second (FEV₁), and proportion of CAT responders at Week 12.</p><p><strong>Results: </strong>From 14 October 2022 to 25 June 2023, 460 participants were enrolled; 392 (85.2%) completed the study treatment. After a 12-week treatment, there was a clinically meaningful CFB in CAT score with a mean of -6.81 (95% CI = -7.28-6.33); the proportion of CAT responders (≥2 points reduction from baseline) was 86%; the mean CFB in mMRC score was -0.52 (95% CI = -0.60∼-0.43); and pre-dose FEV₁ showed a clinically meaningful improvement from baseline with a mean of 0.13 L (95% CI = 0.10 ∼ 0.16). During the treatment, 10 (2.2%) participants reported FF/UMEC/VI-related adverse events.</p><p><strong>Conclusion: </strong>In real-world clinical practice in China, FF/UMEC/VI effectively improved symptoms and lung function in patients with symptomatic COPD and was well-tolerated.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1363-1372"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linking histological healing to quality of life: real-world insights into golimumab therapy in ulcerative colitis.","authors":"Rodrigo Galhardi Gasparini, Carlos Taxonera, Antônio José Tibúrcio Alves Júnior, Bianca Loyo Pona Schiavetti, Francisco Guilherme Cancela E Penna, Richard Borba Magalhães, Sandro da Costa Ferreira, Renata de Sá Brito Fróes, Carlos Henrique Marques Dos Santos, Cristina Flores, Bruno César da Silva, Rogério Serafim Parra, Alexandre Venâncio, Hélio Rzetelna, Carlos Frederico Pereira Porto Alegre Rosa, Adriana Ribas Andrade","doi":"10.1080/03007995.2025.2535454","DOIUrl":"10.1080/03007995.2025.2535454","url":null,"abstract":"<p><strong>Background: </strong>Ulcerative colitis (UC) significantly impacts patients' quality of life (QoL). Therapeutic strategies have increasingly focused on achieving histological and endoscopic remission in addition to clinical outcomes and patient-reported measures. Real-world data on the effectiveness of golimumab to achieve histologic remission is scarce.</p><p><strong>Methods: </strong>This was a multicenter, cohort study including 73 patients with moderate-to-severe UC treated with golimumab across Brazilian centers. Outcomes were assessed at weeks 24 and 54 and included histological remission (Nancy histological index [NHI]), endoscopic remission (Mayo endoscopic subscore [MES]), inflammatory biomarkers (CRP and fecal calprotectin), and QoL (IBDQ-36). Correlations between histological scores with endoscopic outcomes and QoL were analyzed using Spearman test.</p><p><strong>Results: </strong>At week 24, 32.4% of patients achieved complete histological remission (NHI grade 0), and 80.8% achieved endoscopic remission (MES 0 or 1). At week 54, 55.2% of patients had histological remission and 84.4% of patients achieved endoscopic remission. Mean CRP levels decreased from 13.16 mg/dL at baseline to 1.35 mg/dL at week 54 (<i>p</i> < 0.001), and mean calprotectin decreased from 2113.2 to 106.9 mcg/g (<i>p</i> < 0.001). QoL significantly improved, with IBDQ-36 scores increasing from 121.5 at baseline to 182.1 at week 24 and 194.2 at week 54 (<i>p</i> = 0.002). Significant correlations were observed between NHI with MES and IBDQ-36 at week 24.</p><p><strong>Conclusion: </strong>Golimumab has achieved sustained efficacy in the induction of histological and endoscopic remission and improvement in QoL in patients with moderate-to-severe UC in a real-world setting. These results support the use of golimumab as an effective, patient-centered therapeutic option, particularly when multidimensional disease control is the goal.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1219-1226"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic burden and treatment patterns among patients with mantle cell lymphoma in the United States: a retrospective study of administrative claims data.","authors":"Mahek Garg, Ambika Satija, Yan Song, Eric M Sarpong, Benjamin Meade, James Signorovitch, Katherine Ryland, Monika Raut","doi":"10.1080/03007995.2025.2536612","DOIUrl":"10.1080/03007995.2025.2536612","url":null,"abstract":"<p><strong>Objective: </strong>Mantle cell lymphoma (MCL) is a rare, aggressive form of non-Hodgkin's lymphoma with relatively poor prognosis. The economic burden of MCL warrants further evaluation, especially given an evolving treatment landscape. This study describes current treatment patterns and economic outcomes among patients with MCL in the United States.</p><p><strong>Methods: </strong>This retrospective cohort study identified adult patients with MCL from claims data (October 2015- March 2021). Outcomes included treatment patterns by line of therapy (LOT), monthly healthcare resource use (HRU) rates, and healthcare costs per patient per month (PPPM) overall and in first line (1 L), second line (2 L), third line (3 L), and beyond (3 L+).</p><p><strong>Results: </strong>The study included 696 patients with MCL (mean follow-up: 22 months; mean age: 71 years; 68% male). Bendamustine-based therapies were most common in 1 L (49%), followed by rituximab monotherapy (14%) and R-CHOP (13%). Rituximab monotherapy and ibrutinib-based therapies were the most common in 2 L (27%; 25%) and 3 L (33%; 21%). During follow-up, MCL-related visits accounted for most hospitalizations (69.2%) and >80% of total all-cause costs ($21,477/$25,944 PPPM). Mean total all-cause costs PPPM increased across lines (1 L: $29,301; 2 L: $34,667; 3 L+: $41,423) due to rising MCL-related medical costs (1 L: $23,859; 2 L: $27,933; 3 L+: $33,399). MCL-related hospitalization costs accounted for higher proportions of MCL-related medical costs with increasing LOTs (51.1% in 1 L to 70.0% in 3 L+).</p><p><strong>Conclusions: </strong>Although a range of treatments are used to manage MCL, including targeted therapies such as ibrutinib, there is a high HRU and cost burden driven by disease-related medical costs that increase with subsequent LOTs.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1227-1238"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physician and patient perspectives on the treatment of hypercholesterolaemia: a cross-sectional study to identify disconnects.","authors":"Adie Viljoen, Vivian Auyeung, Holly Foot, Chloe Grimmett, Silvia Bodini, Laura Douglas, Tamara Kaloti, Zoe Moon, Richa Chhabra, Emma Cotterill, Daniel Robinson, Alberico Catapano, Leonardo De Luca, Tim Hollstein, Jules Payne, Matteo Pirro, Anja Vogt, Rob Horne","doi":"10.1080/03007995.2025.2538748","DOIUrl":"10.1080/03007995.2025.2538748","url":null,"abstract":"<p><strong>Objectives: </strong>Implementation of more stringent LDL-C targets, as recommended by ESC/EAS guidelines, may be influenced by physician understanding of patient preferences. We aimed to understand patient preferences for lipid lowering therapy (LLT) management, perceptions of LLT and unmet needs, alongside physician predictions. We also investigated physician and patient therapy choices in two clinical scenarios.</p><p><strong>Methods: </strong>450 physicians (224 primary care and 226 specialists) across Germany, Italy, and the UK were analysed.</p><p><strong>Results: </strong>Patients reported a high prevalence of unmet needs in relation to support with treatment which was not apparent to physicians. Clinicians underestimated the proportion of patients with doubts about their perceived need for LLT (predicted 40%; actual 64%), treatment concerns (predicted 40%; actual 78.7%), and unmet information needs (32% physician agreement; actual 75%). Despite having negative attitudes to existing treatments, 82% of patients were open to treatment intensification if their LLT was suboptimal (vs. 55% physician agreement). Furthermore, only 16.7% of patients believed repeated prescription changes would lead to non-adherence (vs. 52.4% physician agreement). Presented with case studies, physicians chose progressive LLT more often for the high CV risk case with statin intolerance than for the very high CV risk uncontrolled case (82.7% vs. 61.6%). In both cases, approximately 50% of patients chose progressive LLT.</p><p><strong>Conclusion: </strong>More comprehensive physician and patient support is needed to optimize LLT treatment. This should address patient and clinician barriers to treatment escalation and facilitate shared decision-making.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1291-1302"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}